Update on Indications, Interactions and Complications in the Use of Pharmaceuticals 2018
In-Person EventJul 01 - 08, 2018Barcelona, Catalonia, ES
Speakers
OVERVIEW
Update on Indications, Interactions and Complications in the Use of Pharmaceuticals is organized by Continuing Education, Inc and will be held from Jul 01 - 08, 2018 at 7-Night Western Mediterranean Cruise, Barcelona, Catalonia, Spain.
The target audience for this medical event is Physicians, Physician Assistants, Nurses, Nurse Practitioners, Pharmacists. This CME Conference has been approved for a maximum of 12 AMA PRA Category 1 Credits.
Program Purpose / Objectives: Drug Abuse and Misuse (2 hrs)
• Identify the dangers associated with the nonmedical use of prescription and OTC medications.
• Devise ways to prevent medication abuse in your patients and drug diversion/misuse within your practice.
• Compare and contrast challenges with Prescription Drug Monitoring Programs and behind the counter status.
• Discuss the use of marijuana (and its active ingredients) for various medicinal purposes.
Understanding Patient’s Approaches in Self-Care (2 hrs)
• Outline strategies for assessing and counseling patients on the use of OTC products in self-care.
• Describe patient’s attitudes about monitoring devices and diagnostics for self-care.
• Identify new personal healthcare technologies and the impact they may have on patient outcomes.
Optimizing Medication Adherence and Outcomes (2 hrs)
• Create strategies to promote medications adherence among all healthcare providers.
• Describe the impact of poor adherence on clinical and economic outcomes for patient and stakeholders.
• Associate the necessary points within the medication use system in which technology can be employed to reduce medical errors and enhance patient outcomes.
From Pharmacogenomics to Personalized Medicine (2 hrs)
• Distinguish the benefits and limitations of genetic testing and use in managing medications in specific patients.
• Identify new personal health care technologies and the impact they may have on patient outcomes.
• Evaluate various gene-drug (biomarker-drug) pairs with pharmacogenomic applications.
Additional details will be posted as soon as they are available.